New hope for dialysis patients with diabetes: study tests Add-On drug
NCT ID NCT02176681
Summary
This study tested whether adding the medication vildagliptin to insulin therapy improves blood sugar control in people with type 2 diabetes who are on dialysis. It involved 70 participants who were monitored for 12 weeks using continuous glucose monitors to track their sugar levels. The goal was to find safer, more effective treatment options for this high-risk group where standard diabetes pills are not suitable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMODIALYZED, TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AURAL Clinique Sainte Anne
Strasbourg, 67000, France
-
AURAL Colmar
Colmar, 68000, France
-
AURAL Mulhouse
Mulhouse, 68070, France
-
AURAL Strasbourg
Strasbourg, 67200, France
-
CH d'Amiens
Amiens, 80054, France
-
CH de Besançon
Besançon, 25030, France
-
CH de Dijon
Dijon, 21079, France
-
CH de Mulhouse
Mulhouse, 68070, France
-
CH de Nancy
Nancy, 54000, France
-
CH de Valenciennes
Valenciennes, 59300, France
-
Clinique Sainte Anne
Strasbourg, 67000, France
-
Hospices civils de Colmar
Colmar, 68024, France
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
Conditions
Explore the condition pages connected to this study.